Tagged with S

Saudi Arabia Saudi Arabia’s pharmaceutical sector continues its impressive growth leadership within the region. With a 9.1 percent market growth in 2024 and a projected USD 11.6 billion in sales, the Kingdom now commands nearly a third of the entire MENA pharma market. But this story goes far beyond impressive numbers. Through…

Denmark Home to a score of pioneering biopharma players, Denmark has recognized its life sciences industry as a cornerstone of the economy. After forming a public-private partnership forum in 2021, the Danish Life Sciences Council (DLSC), the government laid out an ambitious strategy for the sector. The DLSC has now taken…

Switzerland From its roots as a family-run ophthalmology business to its bold reinvention as a precision oncology biotech, CIS Biopharma is charting a distinctive course through the rapidly evolving life sciences landscape. Leading this transformation, CEO Christoph Schäfer shares the strategic rationale behind the company’s evolution, offering insight into how scientific…

Switzerland Bairbre Hickie, General Manager at Takeda, discusses the company’s strategic priorities in Switzerland, focusing on its commitment to bringing innovative treatments to patients and its role in advancing the life sciences ecosystem. In this interview, Hickie explores Takeda’s approach to partnerships, its focus on rare diseases and oncology, and how…

Saudi Arabia As Saudi Arabia reshapes its healthcare sector, Japanese-headquartered medtech player Terumo is deepening its presence, moving beyond market expansion to integration, innovation, and local manufacturing. Elias El Zoughbi, Country Manager for Terumo in Saudi Arabia, is at the helm of this transformation. Navigating a landscape where global expertise meets national…

Mexico Mexico has a long history of public healthcare reforms that have fluctuated along with the changing tides of the country’s government. The latest is an ambitious plan for the Institute of Social Security and Services for State Workers (ISSSTE). Aimed at expanding the reach of public services, the scheme announced…

Switzerland Nicolas Durand, CEO of Fondation Campus Biotech Geneva, shares insights into the foundation’s unique role as a catalyst for neuroscience and digital health innovation in Switzerland. In this interview, Durand discusses the foundation’s collaborative model, the importance of building critical mass in a specialised domain, and how Fondation Campus Biotech…

Switzerland Nasri Nahas, CEO of Biopôle, shares his vision for one of Europe’s leading life sciences innovation parks and its evolving role within the national and international healthcare ecosystem. In this interview, Nasri discusses Biopôle’s key priorities, including the integration of AI and data, sustainability in life sciences, and the importance…

Switzerland Oliver Kuhn, CEO of Selectchemie, has had a diverse career spanning various sectors, starting in the financial industry before transitioning to healthcare. Under his leadership, Selectchemie has sharpened its strong focus on high-quality APIs, excipients, as well as own dossiers and finished-dose-formulations, setting itself apart through a tailored service that…

Switzerland Once a traditional Swiss pharmaceutical wholesaler, Unipharma has undergone a profound transformation into a globally oriented, strategy-driven partner for hospitals, pharmaceutical, and biotechnology companies. Under the leadership of CEO Simone Maisto, the company has redefined its business model, streamlined its portfolio around high-value therapies, and expanded into emerging markets, all…

Puerto Rico We’re not just reconnecting with our roots—we’re planting new ones. The PDA Puerto Rico chapter is a bridge between our island’s rich pharmaceutical legacy and a future powered by innovation, collaboration, and purpose. The Parenteral Drug Association (PDA) is a non-profit global organisation established in 1946, providing support to the…

Switzerland Five decades since its founding, Helsinn has recently undergone one of the most consequential transformations in its history. Executive Chairman Riccardo Braglia and Group CEO Melanie Rolli reflect on a period marked by strategic separation, operational reinvention, and renewed therapeutic ambition. From navigating a near-collapse to redefining the company’s role…